Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...

Obesity is not a single disease. New research shows distinct biological phenotypes that explain why weight gain and treatment ...

Eli Lilly said its closely watched obesity pill helped patients maintain the majority of their weight loss after they ...

Research suggests certain medications could help build or maintain muscle during weight loss. Here's how they work & how to ...

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

The other experimental drug is bimagrumab, which is designed to help patients on weight loss medications from losing too much ...

Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.

New research reveals that taking a GLP-1 can be equivalent to '10 years of ageing' on the body, if proper precautions aren't ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

When we think of weight-loss strategies, logging plenty of exercise is often top of mind. But what if working out isn’t an ...

In the ATTAIN-MAINTAIN study of its orforglipron candidate, switching to the drug after 72 months of injectable treatment ...

Your ability to move and live independently while recovering from illness during aging, depends on your leg strength which ...